Bruker has signed a definitive agreement to acquire functional cell biology company PhenomeX for $1 per share in an all-cash transaction. The proposed acquisition values PhenomeX at a total equity of approximately $108 million. PhenomeX provides single-cell biology research tools to deliver insights into cellular function and perspectives on phenomes and genotype-to-phenotype linkages. Its solutions include the Beacon optofluidics platform, as well as the IsoLight and IsoSpark proteomics barcoding platform. The Beacon product enables functional characterization of tens of thousands of single cells in parallel, while maintaining the cells in a healthy state for further genomic and proteomic profiling, connecting phenotype with genotype and other multiomic information. The IsoLight and IsoSpark instruments automate multiplexed measurements of the extracellular proteome and of the intracellular proteome of single cells for translational research. According to Mark Munch, president of Bruker NANO Group, PhenomeX’s single-cell analysis platforms are enabling new insights in research into antibody therapeutics, cell line development, cell therapy, and gene therapy. Bruker’s entry into single-cell biology research tools via the acquisition complements its emerging spatial biology business, Munch said. The transaction is not subject to financing conditions and is expected to close in the fourth quarter. After the tender offer closes, PhenomeX will merge into a wholly owned subsidiary of Bruker.